<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification of parenteral and oral cephalosporins</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification of parenteral and oral cephalosporins</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification of parenteral and oral cephalosporins</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">First generation</td> <td class="subtitle1">Second generation</td> <td class="subtitle1">Second generation/ Cephamycins*</td> <td class="subtitle1">Third generation</td> <td class="subtitle1">Fourth generation</td> <td class="subtitle1">Advanced generation and combination agents</td> </tr> <tr class="divider_top"> <td class="subtitle2_left" colspan="6">Parenteral cephalosporins</td> </tr> <tr class="divider_bottom"> <td class="indent1"> <ul> <li>Cefazolin (Ancef, Kefzol)</li> <li>Cephalothin (Keflin, <span style="white-space: nowrap;">Seffin)<sup>¶</sup></span></li> <li>Cephapirin <span style="white-space: nowrap;">(Cefadyl)<sup>¶</sup></span></li> <li>Cephradine <span style="white-space: nowrap;">(Velosef)<sup>¶</sup></span></li> </ul> </td> <td> <ul> <li>Cefamandole <span style="white-space: nowrap;">(Mandol)<sup>¶</sup></span></li> <li>Cefonicid <span style="white-space: nowrap;">(Monocid)<sup>¶</sup></span></li> <li>Cefuroxime (Kefurox, Zinacef)</li> </ul> </td> <td> <ul> <li>Cefmetazole <span style="white-space: nowrap;">(Zefazone)<sup>¶</sup></span></li> <li>Cefotetan (Cefotan)</li> <li>Cefoxitin (Mefoxin)</li> </ul> </td> <td> <ul> <li>Cefoperazone <span style="white-space: nowrap;">(Cefobid)<sup>¶</sup></span></li> <li>Cefotaxime (Claforan)</li> <li>Ceftazidime <span style="white-space: nowrap;">(Fortaz)<sup>Δ</sup></span></li> <li>Ceftizoxime <span style="white-space: nowrap;">(Cefizox)<sup>¶</sup></span></li> <li>Ceftriaxone (Rocephin)</li> <li><span style="white-space: nowrap;">Moxalactam<sup>¶</sup></span></li> </ul> </td> <td> <ul> <li>Cefepime (Maxipime)</li> <li>Cefpirome <span style="white-space: nowrap;">(Cefrom)<sup>¶</sup></span></li> </ul> </td> <td> <ul> <li>Ceftaroline (Teflaro)</li> <li>Cefiderocol (Fetroja)</li> <li>Ceftobiprole <span style="white-space: nowrap;">(Zeftera)<sup>¶</sup></span></li> <li>Ceftolozane-tazobactam (Zerbaxa)</li> <li>Ceftazidime-avibactam (Avycaz, Zavicefta)</li> <li>Cefoperazone-<span style="white-space: nowrap;">sulbactam<sup>¶</sup></span></li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="6">Oral cephalosporins</td> </tr> <tr> <td class="indent1"> <ul> <li>Cefadroxil (Duricef, Ultracef)</li> <li>Cephalexin (Keflex, Biocef, Keftab)</li> <li>Cephradine <span style="white-space: nowrap;">(Velosef)<sup>¶</sup></span></li> </ul> </td> <td> <ul> <li>Cefaclor (Ceclor)</li> <li>Cefprozil (Cefzil)</li> <li>Cefuroxime-axetil (Ceftin)</li> <li>Loracarbef <span style="white-space: nowrap;">(Lorabid)<sup>¶</sup></span></li> </ul> </td> <td> </td> <td> <ul> <li>Cefdinir (Omnicef)</li> <li>Cefditoren <span style="white-space: nowrap;">(Spectracef)<sup>¶</sup></span></li> <li>Cefixime (Suprax)</li> <li>Cefpodoxime-proxetil (Vantin)</li> <li>Ceftibuten <span style="white-space: nowrap;">(Cedax)<sup>¶</sup></span></li> </ul> </td> <td> </td> <td> </td> </tr> </tbody></table></div><div class="graphic_footnotes">* Cefamycins have a chemical structure that is distinct from that of cephalosporins but functionally similar, and they are often classified as cephalosporins.<br/>
¶ Not marketed in the United States.<br/>
Δ Unlike most other third generation cephalosporins, ceftazidime has expected activity against <em>Pseudomonas</em> species; however, it has relatively poor activity against gram-positive organisms.</div><div class="graphic_reference">Original table modified for this publication. Craig WA, Andes DR. Cephalosporins. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Bennett JE, Dolin R, Blaser MJ (Eds), 8th ed, Elsevier, Philadelphia 2015. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 115428 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
